GlassScriptPhysician profile
Sukanya Sil
NPI 1205151446
$2,735.24
in general payments reported to CMS, 2019-2025
18 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $121 · 2022: $213 · 2023: $192 · 2024: $334 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,166.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $271.30 | 2025 | |
| Abbvie INC. | $249.99 | 2025 | |
| Esperion Therapeutics, INC. | $245.44 | 2020-2024 | Nexletol, Nexlizet |
| Pfizer INC. | $235.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $195.01 | 2024-2025 | Wainua, Tezspire |
| Merck Sharp & Dohme LLC | $192.30 | 2023 | Verquvo |
| Teva Pharmaceuticals USA, INC. | $126.00 | 2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.99 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $124.74 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $121.83 | 2025 | Benlysta |
| Alnylam Pharmaceuticals INC. | $121.82 | 2022 | |
| Novo Nordisk INC | $121.35 | 2024 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $120.80 | 2025 | Cobenfy |
| Gilead Sciences, INC. | $107.10 | 2025 | Yeztugo |
| Axsome Therapeutics, INC. | $102.15 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $93.77 | 2025 | |
| Braeburn INC. | $90.87 | 2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukanya Sil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.